Endocrine Abstracts

Today, there are 382 million people living with diabetes. The overwhelming majority have a type 2 diabetes. Metformin is first-line drug is for many of them.

Materials and methods: The study involved 26 patients in mean age 54.46±1.2 years (from 41 to 65), among them, 14 women and 12 men. 21 patients with newly diagnosed diabetes and five patients receiving treatment with sulfonylureas. All patients were prescribed metformin in mean dose 2000 mg. During the study were determined the levels of HbA1c and spontaneous apoptosis before and after treatment. Measurement of apoptosis were performed by flow cytometry.

Results:

Conclusions: Metformin in the treatment of diabetes mellitus leads to a decrease in blood glucose and compensation of diabetes. And also metformin reduces the level of spontaneous apoptosis. However, studies of mitochondrial changes membrane potential revealed statistically (P<0.05) significant reduction cells with signs of apoptosis 15.9±1.7%–11.8±1.2% after 90 days of therapy. It the increase in mitochondrial activity and resistance MNCs that turn points to restore energy components of blood cells. And no changes on indicators of surface markers indicating exactly on stimulatory effect of therapy.